Form 4: ALUMIS CFO Granted 202,225 Stock Options

ALUMIS Inc. Chief Financial Officer John R. Schroer was granted 202,225 stock options with an exercise price of $26.31, vesting over four years.

Summary

• John R. Schroer, Chief Financial Officer of ALUMIS Inc. (ALMS), was granted 202,225 stock options.
• The transaction date for this grant was January 26, 2026.
• The exercise price for these stock options is $26.31 per share.
• The options have an expiration date of January 25, 2036.
• Vesting for these options begins with 25% of the shares on January 26, 2027, with the remaining shares vesting in equal monthly installments over the subsequent 36 months.
• Vesting is contingent upon Mr. Schroer's continuous service to ALUMIS Inc., as defined in the company's 2024 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The grant of stock options to the CFO is a positive event for aligning management incentives with shareholder value, reflecting standard executive compensation practices. It does not, however, indicate a direct operational or financial improvement.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with the long-term performance and shareholder value of ALUMIS Inc.
• This is a standard practice for executive compensation, serving as a retention incentive for key management personnel.

Risks

• The value of the stock options is dependent on the future market price of ALUMIS Inc. common stock exceeding the exercise price of $26.31.
• Vesting of the options is subject to the Reporting Person's continuous service to the Issuer, as defined in the 2024 Equity Incentive Plan, meaning the options could be forfeited if service ceases.

Future Outlook

The vesting schedule for the granted stock options extends over four years, indicating a long-term incentive structure designed to retain the Chief Financial Officer and motivate performance aligned with the company's future growth.

Industry Context

The grant of stock options to a Chief Financial Officer is a common and standard practice in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key executives by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The structure of this executive compensation, involving stock options with a multi-year vesting schedule, is consistent with typical equity incentive plans observed across publicly traded companies in the biotech sector.
• The use of a 2024 Equity Incentive Plan for such grants is a standard corporate governance practice, ensuring compensation is approved and structured according to established policies.

Corporate Governance

Related Party Transactions

• Grant of stock options to the Chief Financial Officer, John R. Schroer, as part of his compensation package, which is a standard related-party transaction for executive compensation.

Stakeholder Impact

• Shareholders: Potential benefit from aligned management incentives, encouraging long-term value creation.
• Employees (CFO): Receives a significant equity-based compensation component, enhancing personal wealth potential tied to company performance.

Next Steps

• John R. Schroer's continued service to ALUMIS Inc. to meet vesting conditions.
• Potential exercise of vested stock options in the future, subject to market conditions and personal financial planning.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to the Chief Financial Officer as part of their compensation package. While it aligns management incentives with shareholder value, it does not provide new fundamental information to warrant a change in investment recommendation based solely on this disclosure. Investors should consider broader company performance and market conditions.

Keywords

ALUMIS, ALMS, Stock Options, CFO, Executive Compensation, Form 4, Insider Transaction, Equity Incentive Plan